B2M and neoplasm: A long-term follow-up study of PPL-DLBCL, the largest known series thus far, noted strong homogeneity among the patients: low clinical risk, early stage, and no bulky tumor mass, normal lactic dehydrogenase and beta 2 microglobulin [11].